Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Anti-VEGF treatments are medications injected into the eye to block a substance called vascular endothelial growth factor (VEGF). Too much VEGF can cause abnormal blood vessels to grow and leak, affecting vision. These treatments help slow or stop this process. They are commonly used for conditions that involve unwanted vessel growth.
read more about anti vegf treatments ...These treatments are used when leaking or fragile blood vessels threaten central vision. They help reduce swelling in the retina and support clearer sight. Many patients receive them for conditions that cause sudden or gradual vision changes. They can also help prevent further damage when vessel growth becomes active.
The medication is injected into the vitreous, the gel-like center of the eye. It blocks VEGF, which helps reduce leakage and limits new vessel growth. This can improve how the retina functions over time. Treatments are given in repeating intervals for continued effect.
Anti-VEGF targets the source of leaking or fragile vessels, while other treatments may focus only on reducing swelling. Laser procedures seal leaking areas but do not block new vessel growth. Steroid treatments can calm inflammation but work differently from VEGF blockers. Anti-VEGF therapy is often chosen when active vessel growth is the main concern.
The eye is numbed before the injection to help reduce discomfort. The procedure is quick and done in an outpatient setting. Some patients notice slight pressure or mild irritation afterward. Follow-up visits help determine when additional doses are needed.
Most patients feel pressure more than pain because the eye is numbed first. The injection itself is quick and done in the clinic. Mild scratchiness or watering afterward is common and usually settles fast. If you have severe pain or a big drop in vision after an injection, contact the clinic urgently.
The medication effect wears off over time, and VEGF activity can return. Repeat dosing helps keep leakage and new vessel growth under control. The schedule is adjusted based on scans and how the retina responds. Some patients need frequent injections at first and fewer later.
The goal is to protect central vision by reducing leakage and swelling in the retina. Many patients also see improvements in sharpness once swelling improves. Even when vision doesn't improve dramatically, treatment can slow progression and prevent worse loss. Follow-up visits are part of tracking whether the retina stays stable.
You might notice mild redness, a gritty feeling, or light sensitivity for a short time. A small floating spot can happen from tiny air bubbles and often clears within a day or two. Most people can return to normal activities quickly. Your provider will tell you what symptoms are normal and what signs mean you should call.
1. Age-Related Macular Degeneration (AMD). American Academy of Ophthalmology (AAO). https://www.aao.org/eye-health/diseases/amd-macular-degeneration. Accessed January 29, 2026.
2. Age-Related Macular Degeneration. National Eye Institute (NEI), NIH. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration. Accessed January 29, 2026.
3. Intravitreal Injections. American Society of Retina Specialists (ASRS). https://www.asrs.org/patients/retinal-treatments/5/intravitreal-injections. Accessed January 29, 2026.
4. Lucentis (ranibizumab) Prescribing Information. U.S. Food and Drug Administration (FDA) Drugs@FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/. Accessed January 29, 2026.
5. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration (CATT). PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/21526923/. Accessed January 29, 2026.
6. Aflibercept Injection. MedlinePlus (National Library of Medicine). https://medlineplus.gov/druginfo/meds/. Accessed January 29, 2026.